Home > Browse Issues > Vol.40 No.3
Advances of CAR-T Immunotherapy for Cancer
Lin Caiyao, Muhammad Kalim, Liang Keying, Zhan Jinbiao*
Department of Biochemistry and Genetics, Zhejiang University School of Medicine, Hangzhou 310058, China
Abstract: Chimeric antigen receptor T (CAR-T) cell immunotherapy is a method for engineering recombinant immunoreceptor based on an antibody-derived fragment which endows T cells with the ability to recognize specifically tumor-associated antigens (TAA) with independence of the expression of major histocompatibility complex (MHC) molecules. Clinical trials of CAR-T cells therapy for relapsed or refractory B cell malignancies have demonstrated impressive results. As a milestone， recently a Novartis product―CTL019 is approved by the US FDA for such malignancies. Besides the blood malignancies， CAR-T immunotherapy in treatment of glioblastoma， prostate cancer NSCLC， and other solid tumors also made progress. The immunotherapy is becoming one of the most promising cancer therapy. In this article， we focus on the major challenges in the further development and strategies for increasing anti-tumor activity and safety.
CN
EN